Kongming Wu

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8377603/kongming-wu-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

133 6,606 49 77 g-index

139 8,978 10.6 6.42 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
133	Combination strategies with PD-1/PD-L1 blockade: current advances and future directions <i>Molecular Cancer</i> , 2022 , 21, 28	42.1	22
132	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer <i>Frontiers in Immunology</i> , 2022 , 13, 827921	8.4	4
131	Notch signaling pathway: architecture, disease, and therapeutics <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 95	21	11
130	Targeting polarized phenotype of microglia via IL6/JAK2/STAT3 signaling to reduce NSCLC brain metastasis <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 52	21	3
129	Tumor organoids: applications in cancer modeling and potentials in precision medicine <i>Journal of Hematology and Oncology</i> , 2022 , 15, 58	22.4	3
128	Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies <i>Experimental Hematology and Oncology</i> , 2021 , 10, 60	7.8	5
127	Roles of Microvesicles in Tumor Progression and Clinical Applications. <i>International Journal of Nanomedicine</i> , 2021 , 16, 7071-7090	7.3	7
126	Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 18	7.8	27
125	The biology of combination immunotherapy in recurrent metastatic head and neck cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2021 , 136, 106002	5.6	3
124	Rapid spread of a densovirus in a major crop pest following wide-scale adoption of Bt-cotton in China. <i>ELife</i> , 2021 , 10,	8.9	1
123	The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. <i>International Journal of Cancer</i> , 2021 , 148, 2640-2651	7.5	28
122	Immune signature-based risk stratification and prediction of immune checkpoint inhibitor efficacy for lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1705-1719	7.4	26
121	Prognostic significance of KRT19 in Lung Squamous Cancer. <i>Journal of Cancer</i> , 2021 , 12, 1240-1248	4.5	3
120	Regulation of PD-L1 expression in the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 10	22.4	65
119	The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-land PD-L1. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 27	22.4	30
118	MiRNA-mediated EMT and CSCs in cancer chemoresistance. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 12	7.8	18
117	Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. <i>Biomarker Research</i> , 2021 , 9, 55	8	13

116	Advances of Targeted Therapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 719896	5.3	5
115	Combine and conquer: manganese synergizing anti-TGF-IPD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 146	22.4	13
114	Synergistic resistance of Helicoverpa armigera to Bt toxins linked to cadherin and ABC transporters mutations. <i>Insect Biochemistry and Molecular Biology</i> , 2021 , 137, 103635	4.5	2
113	Recent advances and challenges of bispecific antibodies in solid tumors <i>Experimental Hematology and Oncology</i> , 2021 , 10, 56	7.8	5
112	CD44 as a tumor biomarker and therapeutic target. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 36	7.8	52
111	NRF2-Driven Transcription in Human Lung Cancer. <i>Molecular Cancer Research</i> , 2020 , 18, 1465-1476	6.6	3
110	RDGN-based predictive model for the prognosis of breast cancer. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 13	7.8	5
109	The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. Journal of Hematology and Oncology, 2020 , 13, 72	22.4	55
108	Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. <i>BioMed Research International</i> , 2020 , 2020, 4169691	3	13
107	The role of cancer-derived microRNAs in cancer immune escape. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 25	22.4	74
106	Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. Aging, 2020, 12, 22869-2	28,961	10
105	Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. Journal of Cancer, 2020 , 11, 153-167	4.5	9
104	Ferritins as natural and artificial nanozymes for theranostics. <i>Theranostics</i> , 2020 , 10, 687-706	12.1	51
103	The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. Experimental Hematology and Oncology, 2020 , 9, 27	7.8	8
102	Cadherin repeat 5 mutation associated with Bt resistance in a field-derived strain of pink bollworm.		
102	Scientific Reports, 2020 , 10, 16840	4.9	3
101		4·9 5·3	8
	Scientific Reports, 2020 , 10, 16840 Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database		

98	The roles of exosomes in cancer drug resistance and its therapeutic application. <i>Clinical and Translational Medicine</i> , 2020 , 10, e257	5.7	20
97	Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. <i>Integrative Cancer Therapies</i> , 2019 , 18, 1534735419876351	3	23
96	Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 98	22.4	63
95	EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival. <i>Frontiers in Oncology</i> , 2019 , 9, 26	5.3	6
94	Dachshund Depletion Disrupts Mammary Gland Development and Diverts the Composition of the Mammary Gland Progenitor Pool. <i>Stem Cell Reports</i> , 2019 , 12, 135-151	8	5
93	Transposon insertion causes cadherin mis-splicing and confers resistance to Bt cotton in pink bollworm from China. <i>Scientific Reports</i> , 2019 , 9, 7479	4.9	18
92	SALL4 induces radioresistance in nasopharyngeal carcinoma via the ATM/Chk2/p53 pathway. <i>Cancer Medicine</i> , 2019 , 8, 1779-1792	4.8	23
91	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 27	22.4	107
90	Recent progress on the interaction between insects and Bacillus thuringiensis crops. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2019 , 374, 20180316	5.8	45
89	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. <i>Molecular Cancer</i> , 2019 , 18, 60	42.1	169
88	Pink Bollworm Resistance to Bt Toxin Cry1Ac Associated with an Insertion in Cadherin Exon 20. <i>Toxins</i> , 2019 , 11,	4.9	17
87	Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 35	22.4	98
86	A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 355	12.8	28
85	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. <i>Molecular Cancer</i> , 2019 , 18, 125	42.1	113
84	The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 26	7.8	32
83	Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. <i>Molecular Cancer</i> , 2019 , 18, 155	42.1	353
82	CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1515	5.3	15
81	Advances and perspectives of PARP inhibitors. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 29	7.8	52

80	SIX1 Activates STAT3 Signaling to Promote the Proliferation of Thyroid Carcinoma via EYA1. <i>Frontiers in Oncology</i> , 2019 , 9, 1450	5.3	17
79	Blocking TGF-Lignaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor. <i>OncoTargets and Therapy</i> , 2019 , 12, 9527-9538	4.4	48
78	Resistance to Bacillus thuringiensis linked with a cadherin transmembrane mutation affecting cellular trafficking in pink bollworm from China. <i>Insect Biochemistry and Molecular Biology</i> , 2018 , 94, 28	-3 5 5	26
77	Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis. <i>Clinical Breast Cancer</i> , 2018 , 18, e875-e882	2 3	3
76	Gut microbiome modulates efficacy of immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 47	22.4	76
75	DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 53	22.4	42
74	Developing TRAIL/TRAIL death receptor-based cancer therapies. <i>Cancer and Metastasis Reviews</i> , 2018 , 37, 733-748	9.6	80
73	Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer. <i>Clinical Epigenetics</i> , 2018 , 10, 69	7.7	10
72	EGFR-TKIs resistance via EGFR-independent signaling pathways. <i>Molecular Cancer</i> , 2018 , 17, 53	42.1	112
71	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018 , 17, 129	42.1	280
70	The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018 , 7, 28	7.8	63
69	Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. <i>Experimental Hematology and Oncology</i> , 2018 , 7, 30	7.8	83
68	The regulation of cytokine signaling by retinal determination gene network pathway in cancer. <i>OncoTargets and Therapy</i> , 2018 , 11, 6479-6487	4.4	11
67	Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. <i>Cancer Management and Research</i> , 2018 , 10, 4039-4050	3.6	8
66	Organoid technology and applications in cancer research. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 116	22.4	123
65	MAT1 correlates with molecular subtypes and predicts poor survival in breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018 , 30, 351-363	3.8	3
64	A Single Point Mutation Resulting in Cadherin Mislocalization Underpins Resistance against Toxin in Cotton Bollworm. <i>Journal of Biological Chemistry</i> , 2017 , 292, 2933-2943	5.4	30
63	Recent advances of highly selective CDK4/6 inhibitors in breast cancer. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 97	22.4	100

62	Chimeric antigen receptor T cells: a novel therapy for solid tumors. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 78	22.4	179
61	Recent advances of bispecific antibodies in solid tumors. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 155	22.4	89
60	Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 31	7.8	44
59	Targeting interlukin-6 to relieve immunosuppression in tumor microenvironment. <i>Tumor Biology</i> , 2017 , 39, 1010428317712445	2.9	37
58	Prostate-specific IL-6 transgene autonomously induce prostate neoplasm through amplifying inflammation in the prostate and peri-prostatic adipose tissue. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 14	22.4	11
57	DACH1 suppresses breast cancer as a negative regulator of CD44. Scientific Reports, 2017, 7, 4361	4.9	22
56	OK-432 (Sapylin) Reduces Seroma Formation After Axillary Lymphadenectomy in Breast Cancer. <i>Journal of Investigative Surgery</i> , 2017 , 30, 1-5	1.2	10
55	The clinical significance of CXCL5 in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2017 , 10, 556	1- <u>4</u> 5.5 ₄ 73	27
54	ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells. <i>Oncotarget</i> , 2017 , 8, 21626-21638	3.3	20
53	Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. <i>Oncotarget</i> , 2017 , 8, 62330-62338	3.3	5
52	Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. <i>Oncotarget</i> , 2017 , 8, 81754-81775	3.3	22
51	The CXCL8-CXCR1/2 pathways in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2016 , 31, 61-71	17.9	271
50	The expression profile and clinic significance of the SIX family in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 119	22.4	44
49	Emerging roles of Nrf2 signal in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 14	22.4	42
48	The DACH/EYA/SIX gene network and its role in tumor initiation and progression. <i>International Journal of Cancer</i> , 2016 , 138, 1067-75	7.5	52
47	GRIM-19 inhibition induced autophagy through activation of ERK and HIF-1[hot STAT3 in Hela cells. <i>Tumor Biology</i> , 2016 , 37, 9789-96	2.9	11
46	The retinal determination gene network: from developmental regulator to cancer therapeutic target. <i>Oncotarget</i> , 2016 , 7, 50755-50765	3.3	23
45	Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. <i>OncoTargets and Therapy</i> , 2016 , 9, 431-44	4.4	42

(2015-2016)

44	A novel paclitaxel-loaded poly(d,l-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment. <i>International Journal of Nanomedicine</i> , 2016 , 11, 2119-31	7.3	13
43	Resistance to Bacillus thuringiensis Mediated by an ABC Transporter Mutation Increases Susceptibility to Toxins from Other Bacteria in an Invasive Insect. <i>PLoS Pathogens</i> , 2016 , 12, e1005450	7.6	34
42	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016 , 9, 83	22.4	36
41	CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. <i>International Journal of Oncology</i> , 2016 , 49, 1343-50	4.4	38
40	Left lower limb may be a forbidden region for indwelling needle during operation. <i>Thrombosis Research</i> , 2016 , 144, 165-8	8.2	
39	Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. <i>Scientific Reports</i> , 2015 , 5, 10338	4.9	81
38	The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module. <i>Cancer Research</i> , 2015 , 75, 1992-2004	10.1	23
37	Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 95	22.4	70
36	Notch signaling: an emerging therapeutic target for cancer treatment. <i>Cancer Letters</i> , 2015 , 369, 20-7	9.9	260
35	Large-scale test of the natural refuge strategy for delaying insect resistance to transgenic Bt crops. <i>Nature Biotechnology</i> , 2015 , 33, 169-74	44.5	139
34	The inhibitory effects of AR/miR-190a/YB-1 negative feedback loop on prostate cancer and underlying mechanism. <i>Scientific Reports</i> , 2015 , 5, 13528	4.9	21
33	The role of CD44 in epithelial-mesenchymal transition and cancer development. <i>OncoTargets and Therapy</i> , 2015 , 8, 3783-92	4.4	114
32	A toxin-binding alkaline phosphatase fragment synergizes Bt toxin Cry1Ac against susceptible and resistant Helicoverpa armigera. <i>PLoS ONE</i> , 2015 , 10, e0126288	3.7	32
31	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. <i>PLoS ONE</i> , 2015 , 10, e0131689	3.7	51
30	Endogenous Dach1 in cancer. <i>Oncoscience</i> , 2015 , 2, 803-4	0.8	6
29	DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/Etatenin signaling. <i>Oncotarget</i> , 2015 , 6, 8621-34	3.3	30
28	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. <i>Oncotarget</i> , 2015 , 6, 5877-88	3.3	33
27	Interplay of retinal determination gene network with TGF-Isignaling pathway in epithelial-mesenchymal transition. Stem Cell Investigation, 2015, 2, 12	5.1	6

26	Quantitative analysis of fitness costs associated with the development of resistance to the Bt toxin Cry1Ac in Helicoverpa armigera. <i>Scientific Reports</i> , 2014 , 4, 5629	4.9	29
25	Mis-splicing of the ABCC2 gene linked with Bt toxin resistance in Helicoverpa armigera. <i>Scientific Reports</i> , 2014 , 4, 6184	4.9	101
24	Silencing DACH1 promotes esophageal cancer growth by inhibiting TGF-13 ignaling. <i>PLoS ONE</i> , 2014 , 9, e95509	3.7	20
23	DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. Journal of Hematology and Oncology, 2014 , 7, 73	22.4	42
22	Epigenetic silencing of DACH1 induces the invasion and metastasis of gastric cancer by activating TGF-Bignalling. <i>Journal of Cellular and Molecular Medicine</i> , 2014 , 18, 2499-511	5.6	27
21	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 87	22.4	149
20	Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. <i>Cancer Research</i> , 2014 , 74, 829-39	10.1	53
19	CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling. <i>Oncotarget</i> , 2014 , 5, 10293-306	3.3	42
18	Dachshund binds p53 to block the growth of lung adenocarcinoma cells. <i>Cancer Research</i> , 2013 , 73, 320	52±7⁄41	49
17	EYA1 phosphatase function is essential to drive breast cancer cell proliferation through cyclin D1. <i>Cancer Research</i> , 2013 , 73, 4488-99	10.1	66
16	Epigenetic silencing of DACH1 induces loss of transforming growth factor-II antiproliferative response in human hepatocellular carcinoma. <i>Hepatology</i> , 2013 , 58, 2012-22	11.2	49
15	Epigenetic regulation of DACH1, a novel Wnt signaling component in colorectal cancer. <i>Epigenetics</i> , 2013 , 8, 1373-83	5.7	63
14	Acetylation of the cell-fate factor dachshund determines p53 binding and signaling modules in breast cancer. <i>Oncotarget</i> , 2013 , 4, 923-35	3.3	24
13	Diverse genetic basis of field-evolved resistance to Bt cotton in cotton bollworm from China. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 10275-80	11.5	135
12	Reduced levels of membrane-bound alkaline phosphatase are common to lepidopteran strains resistant to Cry toxins from Bacillus thuringiensis. <i>PLoS ONE</i> , 2011 , 6, e17606	3.7	115
11	Cell fate determination factor Dachshund reprograms breast cancer stem cell function. <i>Journal of Biological Chemistry</i> , 2011 , 286, 2132-42	5.4	67
10	Attenuation of Forkhead signaling by the retinal determination factor DACH1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 6864-9	11.5	50
9	The Dachshund gene in development and hormone-responsive tumorigenesis. <i>Trends in Endocrinology and Metabolism</i> , 2010 , 21, 41-9	8.8	56

LIST OF PUBLICATIONS

8	The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. <i>Cancer Research</i> , 2009 , 69, 5752-60	10.1	50
7	The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. <i>Cancer Research</i> , 2009 , 69, 3347-55	10.1	66
6	Reduction of Bacillus thuringiensis Cry1Ac toxicity against Helicoverpa armigera by a soluble toxin-binding cadherin fragment. <i>Journal of Insect Physiology</i> , 2009 , 55, 686-93	2.4	24
5	Mutation of an aminopeptidase N gene is associated with Helicoverpa armigera resistance to Bacillus thuringiensis Cry1Ac toxin. <i>Insect Biochemistry and Molecular Biology</i> , 2009 , 39, 421-9	4.5	126
4	Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 6924-9	11.5	78
3	Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. <i>Molecular Biology of the Cell</i> , 2007 , 18, 755-67	3.5	57
2	DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. <i>Molecular and Cellular Biology</i> , 2006 , 26, 7116-29	4.8	103
1	DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. <i>Journal of Biological Chemistry</i> , 2003 , 278, 51673-84	5.4	109